Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
JW (Cayman) Therapeutics Co. Ltd. ( (HK:2126) ) has issued an announcement.
JW (Cayman) Therapeutics Co. Ltd. has announced its upcoming annual general meeting scheduled for June 26, 2025, in Shanghai, China. Key agenda items include the adoption of the 2024 financial statements, re-election of directors, re-appointment of Deloitte Touche Tohmatsu as auditors, and approval for directors to manage share-related transactions. This meeting is crucial for setting the company’s strategic direction and ensuring continued governance and financial oversight.
More about JW (Cayman) Therapeutics Co. Ltd.
JW (Cayman) Therapeutics Co. Ltd. is a company incorporated in the Cayman Islands, operating in the biotechnology sector. It focuses on developing and commercializing innovative cell-based therapies for cancer treatment.
Average Trading Volume: 2,066,705
Technical Sentiment Signal: Sell
Current Market Cap: HK$645M
For a thorough assessment of 2126 stock, go to TipRanks’ Stock Analysis page.